Lung Nodule Characterization by Artificial Intelligence Techniques

NCT ID: NCT03843164

Last Updated: 2019-04-04

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-03-12

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Management of incidental lung nodule is difficult and mainly based on simple morphometric characteristics such as maximum size and shape. Radiomics could play a role in simplifying this management by orientating towards a benign or a malignant origin, by comparing advanced characteristics to a large database of lung nodules.

The primary purpose is to evaluate the performances of a novel tool based on radiomics to characterize incidental lung nodules, discovered on computed tomography.

The secondary objectives are:

* to evaluate the variation in the performances of the software based on various technical aspects of the CT, such as radiation dose, reconstruction algorithm, type of scanner,…
* to compare the performances of this software to those of expert readers,
* to analyze the potential impact of this software on patient's management.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incidental Lung Nodule

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (at least 18 years old);
* With a chest CT acquired between Jan 1 2012 and Oct 1 2018 at the Strasbourg University Hospital;
* CT being available over the PACS and exhibiting at least one lung nodule;
* Patient having given its authorization for the exploitation of his medical data for this research.

Exclusion Criteria

* Patient having expressed direct opposition to participation in this study;
* Patient under juridical protection;
* Patient under tutelage or guardianship.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Service de Radiologie B - NHC

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mickaël OHANA, MD

Role: CONTACT

33 3 69 55 11 17

Aissam LABANI, MD

Role: CONTACT

33 3 69 55 11 17

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mickaël OHANA, MD

Role: primary

33 3 69 55 11 17

Aissam LABANI, MD

Role: backup

33 3 69 55 11 17

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

7311

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.